PH12019500368A1 - Inhibitors of cellular metabolic processes - Google Patents
Inhibitors of cellular metabolic processesInfo
- Publication number
- PH12019500368A1 PH12019500368A1 PH12019500368A PH12019500368A PH12019500368A1 PH 12019500368 A1 PH12019500368 A1 PH 12019500368A1 PH 12019500368 A PH12019500368 A PH 12019500368A PH 12019500368 A PH12019500368 A PH 12019500368A PH 12019500368 A1 PH12019500368 A1 PH 12019500368A1
- Authority
- PH
- Philippines
- Prior art keywords
- inhibitors
- metabolic processes
- cellular metabolic
- compounds
- useful
- Prior art date
Links
- 230000019522 cellular metabolic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- ZTNQNZDNHUAVEI-UHFFFAOYSA-N CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 Chemical class CC=1SC2=C(N=1)C=CC(=C2)C1=C(NC=2N(C1=O)N=C(C=2C1=CC=CC=C1)C1=CC=CC=C1)NC1=NC=CC=C1 ZTNQNZDNHUAVEI-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA), wherein RA, RB, RC, RD, and RE are defined herein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/097524 WO2018039972A1 (en) | 2016-08-31 | 2016-08-31 | Inhibitors of cellular metabolic processes |
| PCT/US2017/049439 WO2018045071A1 (en) | 2016-08-31 | 2017-08-30 | Inhibitors of cellular metabolic processes |
| US201862548738P | 2018-06-22 | 2018-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019500368A1 true PH12019500368A1 (en) | 2019-10-21 |
Family
ID=68290460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019500368A PH12019500368A1 (en) | 2016-08-31 | 2019-02-21 | Inhibitors of cellular metabolic processes |
Country Status (1)
| Country | Link |
|---|---|
| PH (1) | PH12019500368A1 (en) |
-
2019
- 2019-02-21 PH PH12019500368A patent/PH12019500368A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190157A (en) | Inhibitors of cellular metabolic processes | |
| PH12016502179A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| EA201790376A1 (en) | INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1 | |
| MY191796A (en) | Heterocyclic compounds as lsd1 inhibitors | |
| EA201790082A1 (en) | INHIBITORS OF LYSINE-SPECIFIC DEMITILASE-1 | |
| MX376632B (en) | LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITORS. | |
| MX376207B (en) | LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITORS. | |
| PH12017500293A1 (en) | Boronic acid derivatives | |
| EA201692483A1 (en) | HYSTON METHYLASE INHIBITORS | |
| MX2017004037A (en) | Boronic acid derivatives. | |
| MX2017004043A (en) | Boronic acid derivatives. | |
| MX2017004046A (en) | Boronic acid derivatives. | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX2014013758A (en) | Thiazolecarboxamide derivatives for use as nampt inhibitors. | |
| MX388409B (en) | COMPOSITIONS AND METHODS FOR TREATING CANCERS. | |
| MX2021009044A (en) | Boron-containing proteasome inhibitors for use after primary cancer therapy. | |
| EA201792288A1 (en) | METHODS OF TREATING CANCER | |
| EA201790604A1 (en) | Inhibitors of histonedehylase | |
| PH12019500368A1 (en) | Inhibitors of cellular metabolic processes | |
| NZ751515B2 (en) | Inhibitors of cellular metabolic processes | |
| EA201990556A1 (en) | CELLULAR METABOLIC INHIBITORS | |
| UA109932C2 (en) | CYCLOPROPYLAMINS AS LSD1 INHIBITORS | |
| HK1236097A1 (en) | Boron-containing proteasome inhibitors for use after primary cancer therapy |